Guillain-Barre Syndrome (GBS) is a neurological syndrome in which the axon andmyelin sheaths of the peripheral nervous system are attacked by the immune system. GBS is characterised by its rapid onset and ascending paralysis. It is classified as post-infectious, as its onset is often preceded by an infection, most commonly Campylobacter jejuni. The mechanism of GBS is not fully understood although it is believed that antigens such as GM1 on the virus capsule mimic those in gangliosides on C. jejuni. Thus leading to T-cell cross-reactivity, and ultimately host nerve cell damage. Currently, plasmapheresis and intravenous immunoglobin (IVIG) administration are the most effective treatments. Advances in this field are needed to better understand the mechanisms behind this condition at the molecular and cellular level, and ultimately improve mortality in the post-treatment period.